Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin with or without retinoic acid and testosterone undecanoate for anemia in lower-risk myelodysplastic syndrome
ChiCTR2000030594Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of erythropoietin, tretinoin and testosterone undecanoate in myelodysplastic syndrome (MDS) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Hemoglobin response rate. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
erythropoietintretinointestosterone undecanoate
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2000030594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030594.